These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 1333013)

  • 1. Opioid agonist and antagonist activities of morphindoles related to naltrindole.
    Portoghese PS; Larson DL; Sultana M; Takemori AE
    J Med Chem; 1992 Nov; 35(23):4325-9. PubMed ID: 1333013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
    Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
    J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of peptidomimetic delta opioid receptor antagonists using the message-address concept.
    Portoghese PS; Sultana M; Takemori AE
    J Med Chem; 1990 Jun; 33(6):1714-20. PubMed ID: 2160538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of 7-arylmorphinans. Probing the "address" requirements for selectivity at opioid delta receptors.
    Gao P; Larson DL; Portoghese PS
    J Med Chem; 1998 Jul; 41(16):3091-8. PubMed ID: 9685249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and delta-opioid receptor antagonist activity of a naltrindole analogue with a regioisomeric indole moiety.
    Portoghese PS; Ohkawa S; Moe ST; Takemori AE
    J Med Chem; 1994 Jun; 37(12):1886-8. PubMed ID: 8021929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A remarkable change of opioid receptor selectivity on the attachment of a peptidomimetic kappa address element to the delta antagonist, natrindole: 5'-[N2-alkylamidino)methyl]naltrindole derivatives as a novel class of kappa opioid receptor antagonists.
    Olmsted SL; Takemori AE; Portoghese PS
    J Med Chem; 1993 Jan; 36(1):179-80. PubMed ID: 8380614
    [No Abstract]   [Full Text] [Related]  

  • 7. Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphinans.
    Ananthan S; Kezar HS; Carter RL; Saini SK; Rice KC; Wells JL; Davis P; Xu H; Dersch CM; Bilsky EJ; Porreca F; Rothman RB
    J Med Chem; 1999 Sep; 42(18):3527-38. PubMed ID: 10479286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of spacer and address components in peptidomimetic delta opioid receptor antagonists related to naltrindole.
    Portoghese PS; Nagase H; MaloneyHuss KE; Lin CE; Takemori AE
    J Med Chem; 1991 May; 34(5):1715-20. PubMed ID: 1851846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The selectivity of the opioid antagonist, naltrindole, for delta-opioid receptors.
    Rogers H; Hayes AG; Birch PJ; Traynor JR; Lawrence AJ
    J Pharm Pharmacol; 1990 May; 42(5):358-9. PubMed ID: 1976787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
    Ananthan S; Khare NK; Saini SK; Seitz LE; Bartlett JL; Davis P; Dersch CM; Porreca F; Rothman RB; Bilsky EJ
    J Med Chem; 2004 Mar; 47(6):1400-12. PubMed ID: 14998329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary delta opioid antagonist activity.
    Salvadori S; Balboni G; Guerrini R; Tomatis R; Bianchi C; Bryant SD; Cooper PS; Lazarus LH
    J Med Chem; 1997 Sep; 40(19):3100-8. PubMed ID: 9301674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The opioid activity and receptor selectivity of fluorinated Leu5 enkephalin analogues in vitro and in vivo.
    Watanabe J; Tokuyama S; Takahashi M; Kaneto H; Maeda M; Kawasaki K; Taguchi T; Kobayashi Y; Yamamoto Y; Shimokawa K
    J Pharmacobiodyn; 1991 Feb; 14(2):101-5. PubMed ID: 1651391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. delta Opioid affinity and selectivity of 4-hydroxy-3-methoxyindolomorphinan analogues related to naltrindole.
    Coop A; Rothman RB; Dersch C; Partilla J; Porreca F; Davis P; Jacobson AE; Rice KC
    J Med Chem; 1999 May; 42(9):1673-9. PubMed ID: 10229636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, opioid receptor binding, and functional activity of 5'-substituted 17-cyclopropylmethylpyrido[2',3':6,7]morphinans.
    Ananthan S; Kezar HS; Saini SK; Khare NK; Davis P; Dersch CM; Porreca F; Rothman RB
    Bioorg Med Chem Lett; 2003 Feb; 13(3):529-32. PubMed ID: 12565965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delta opioid antagonist activity and binding studies of regioisomeric isothiocyanate derivatives of naltrindole: evidence for delta receptor subtypes.
    Portoghese PS; Sultana M; Nelson WL; Klein P; Takemori AE
    J Med Chem; 1992 Oct; 35(22):4086-91. PubMed ID: 1331455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of 14-alkoxymorphinans. 11. 3-Hydroxycyprodime and analogues: opioid antagonist profile in comparison to cyprodime.
    Schmidhammer H; Jennewein HK; Krassnig R; Traynor JR; Patel D; Bell K; Froschauer G; Mattersberger K; Jachs-Ewinger C; Jura P
    J Med Chem; 1995 Aug; 38(16):3071-7. PubMed ID: 7636870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naltrindole, a highly selective and potent non-peptide delta opioid receptor antagonist.
    Portoghese PS; Sultana M; Takemori AE
    Eur J Pharmacol; 1988 Jan; 146(1):185-6. PubMed ID: 2832195
    [No Abstract]   [Full Text] [Related]  

  • 18. In vivo and in vitro investigation of naltrindole, a delta-opioid antagonist.
    Ayres EA; Davis P; Burks TF
    Proc West Pharmacol Soc; 1990; 33():55-63. PubMed ID: 2177196
    [No Abstract]   [Full Text] [Related]  

  • 19. BU48: a novel buprenorphine analog that exhibits delta-opioid-mediated convulsions but not delta-opioid-mediated antinociception in mice.
    Broom DC; Guo L; Coop A; Husbands SM; Lewis JW; Woods JH; Traynor JR
    J Pharmacol Exp Ther; 2000 Sep; 294(3):1195-200. PubMed ID: 10945877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Agonist and antagonist opioid activity of axial and equatorial conformations of S-methyl- and S-allyl-morphinans.
    Lemaire S; Belleau B; Jolicoeur FB
    Eur J Pharmacol; 1994 Jun; 258(1-2):111-8. PubMed ID: 7925589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.